[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100374868":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":41,"locations":51,"responsibleParty":66,"collaborators":46,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":46,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":46,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":46,"overallStatus":54,"whyStopped":46,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Rifaximin","ACTIVE_COMPARATOR","550 mg Rifaximin tablets twice daily for six months.",[13],"Drug: Rifaximin",{"label":15,"type":16,"description":17,"interventionNames":18},"Nitazoxanide","EXPERIMENTAL","500 mg Nitazoxanide tablets twice daily for six months.",[19],"Drug: Nitazoxanide",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Rifaximin 550 mg twice daily for 6 months",[9],[26],"Gastrobiotic, Trencedia",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Nitazoxanide 500 mg twice daily for 6 months",[15],[31],"Nanazoxid",[33,36,38],{"name":34,"affiliation":5,"role":35},"Khadija Ahmed Glal, Msc","PRINCIPAL_INVESTIGATOR",{"name":37,"affiliation":5,"role":35},"Tarek Mohamed Mostafa, ass, Prof.",{"name":39,"affiliation":40,"role":35},"Sherief Abd-Elsalam, Ass. Prof.","Tanta University - Tropical Medicine Department",[42,48],{"name":43,"role":44,"phone":45,"phoneExt":46,"email":47},"Sherief Abd-Elsalam, ass. prof.","CONTACT","00201147773440",null,"sheriefabdelsalam@yahoo.com",{"name":49,"role":44,"phone":45,"phoneExt":46,"email":50},"sherief abd-elsalam, ass. prof.","sherif_tropical@yahoo.com",[52],{"facility":53,"status":54,"city":55,"state":46,"zip":46,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Sherief Abd-Elsalam","RECRUITING","Tanta","Egypt","EG",{"type":59,"coordinates":60},"Point",[61,62],31.00192,30.78847,{"lat":62,"lon":61},[65],{"name":53,"role":44,"phone":46,"phoneExt":46,"email":46},{"type":35,"investigatorFullName":53,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":46,"oldOrganization":46},"Ass. Prof. Tropical Medicine","100374868","phase-3-efficacy-and-safety-of-nitazoxanide-in-preventing-recurrence-of-hepatic-encephalopathy-100374868",false,"NCT04161053","Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy","Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy","Inclusion Criteria:\n\n* Cirrhotic patient with at least one previous episode of hepatic encephalopathy.\n* Adult Patients aging from 20 to 65 years old\n\nExclusion Criteria:\n\n* Active GIT bleeding.\n* Major psychiatric illness (psychosis \\& epilepsy).\n* Renal insufficiency (S.Cr 2mg\u002Fdl).","ALL","20 Years","65 Years",{"count":79,"type":80},60,"ESTIMATED","INTERVENTIONAL",[83],"PHASE3","Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.",[86],"Hepatic Encephalopathy","2019-11-12",{"date":89,"type":90},"2019-11-13","ACTUAL",{"date":92,"type":90},"2018-11-01",{"date":94,"type":80},"2028-12",{"name":5,"class":6},1]